Catalent vs KBI Biopharma: CDMO Comparison
Side-by-side comparison of Catalent and KBI Biopharma on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Catalent →
76.5
Somerset, NJ (now Novo Holdings)
Signal Score
76/100
Quality (FDA + GMP)
79/100
FDA inspections
10
— NAI / VAI / OAI
3 / 6 / 1
FDA warning letters
2
EMA GMP certificates (active)
14
MHRA GMP certificates (compliant)
16
Clinical programs (matched)
0
Capacity
—
Modalities
AAV, CAR-T, Lentiviral, Plasmid DNA
KBI Biopharma →
83.5
Durham, NC · Boulder, CO
Signal Score
84/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
0 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
Limited
Modalities
AAV, Plasmid DNA
Evaluating Catalent and KBI Biopharma for a program?
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.